Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Exousia Pro's share price for the quarter that ended in Jan. 2021 was $1.5814. Exousia Pro's Shares Outstanding (EOP) for the quarter that ended in Jan. 2021 was 12.49 Mil. Therefore, Exousia Pro's market cap for the quarter that ended in Jan. 2021 was $19.75 Mil.
Exousia Pro's quarterly market cap
declined
from Jul. 2020 ($128.54 Mil) to Oct. 2020 ($25.73 Mil) and
declined
from Oct. 2020 ($25.73 Mil) to Jan. 2021 ($19.75 Mil).
Exousia Pro's annual market cap
declined
from Apr. 2012 ($10.74 Mil) to Apr. 2018 ($0.55 Mil) but then
increased
from Apr. 2018 ($0.55 Mil) to Apr. 2019 ($1.00 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Exousia Pro's Enterprise Value for Today is $0.54 Mil.
Exousia Pro (OTCPK:MAJI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Exousia Pro Market Cap Related Terms
Exousia Pro Market Cap Historical Data
* Premium members only.
The historical data trend for Exousia Pro's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Exousia Pro's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exousia Pro Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exousia Pro's Market Cap distribution charts can be found below:
* The bar in red indicates where Exousia Pro's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Exousia Pro's Market Cap for the fiscal year that ended in Apr. 2019 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exousia Pro (MAJI) has a Market Cap of $0.54 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Exousia Pro and its competitors.
Is Exousia Pro's Market Cap too high?
Exousia Pro's current Market Cap is $0.54 Mil. The Biotechnology industry median Market Cap is 112.70. Exousia Pro's value of $0.54 Mil is 99.5% below this industry median.
How does Exousia Pro's Market Cap compare to HCCH and GRNV?
Exousia Pro's Market Cap of $0.54 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 112.70. Exousia Pro's value of $0.54 Mil is 99.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Exousia Pro's current Market Cap of $0.54 Mil is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Exousia Pro and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exousia Pro's current Market Cap is $0.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exousia Pro stock overvalued right now?
Exousia Pro (MAJI) has a current Market Cap of $0.54 Mil. The current Market Cap is $0.54 Mil and 99.5% below the Biotechnology industry median of 112.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Exousia Pro (MAJI), the current Market Cap is $0.54 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Exousia Pro Inc is a exosome-based biotechnology, develops and manufactures mammalian and plant-based exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company is developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. The platform technology of the company also helps treating a broad spectrum of viral infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAJI has been successfully added to your 